Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This was a Phase 3b clinical study in prostate cancer patients which aimed to compare the
current standard therapy of a gonadotrophin releasing hormone (GnRH) agonist, goserelin (3.6
mg; plus anti-androgen flare protection, bicalutamide), to a novel GnRH antagonist, degarelix
(240 mg starting dose/80 mg maintenance dose) with respect to mean percentage reduction in
prostate volume.
The hypothesis was that degarelix could decrease prostate size at least as effectively as the
combination of a GnRH agonist with an anti-androgen for flare protection.